Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Merck & Co., Inc.
Merck & Co., Inc. News
Jun 14, 2025 - fool.com
These Were the 2 Worst-Performing Stocks in the Dow Jones Industrial Average in May 2025
Jun 13, 2025 - investopedia.com
Merck Gets FDA Approval to Expand Use of Its Top-Selling Drug, Keytruda
Jun 13, 2025 - businesswire.com
FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent
Jun 12, 2025 - businesswire.com
Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs
Merck & Co., Inc. Quantitative Score
About Merck & Co., Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Merck & Co., Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Merck & Co., Inc. Financials
Table Compare
Compare MRK metrics with: | |||
|---|---|---|---|
Earnings & Growth | MRK | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | MRK | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | MRK | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | MRK | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Merck & Co., Inc. Income
Merck & Co., Inc. Balance Sheet
Merck & Co., Inc. Cash Flow
Merck & Co., Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Buy |
| Return on Equity | Strong Buy |
| Return on Assets | Strong Buy |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Sell |
| Price/Book Ratio | Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Merck & Co., Inc. Dividends
| Yield (TTM) | Dividend (TTM) | |
|---|---|---|
Infinity% | 3.2000 |
| Payment Date | Dividend | Frequency |
|---|---|---|
| 2025-07-08 | 0.81 | Quarterly |
| 2025-04-07 | 0.81 | Quarterly |
| 2025-01-08 | 0.81 | Quarterly |
| 2024-10-07 | 0.77 | Quarterly |
| 2024-07-08 | 0.77 | Quarterly |
Historical Market Cap
Shares Outstanding
Merck & Co., Inc. Executives
| Name | Role |
|---|---|
| Mr. Robert M. Davis J.D. | Chairman, President & Chief Executive Officer |
| Dr. Dean Y. Li M.D., Ph.D. | Executive Vice President & President of Merck Research Laboratories |
| Ms. Jennifer L. Zachary J.D. | Executive Vice President & General Counsel |
| Ms. Caroline Litchfield | Executive Vice President & Chief Financial Officer |
| Ms. Betty D. Larson | Executive Vice President & Chief Human Resources Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Robert M. Davis J.D. | Chairman, President & Chief Executive Officer | Male | 1967 | 4.95M |
| Dr. Dean Y. Li M.D., Ph.D. | Executive Vice President & President of Merck Research Laboratories | 1963 | 3.28M | |
| Ms. Jennifer L. Zachary J.D. | Executive Vice President & General Counsel | Female | 1978 | 2.73M |
| Ms. Caroline Litchfield | Executive Vice President & Chief Financial Officer | Female | 1969 | 2.65M |
| Ms. Betty D. Larson | Executive Vice President & Chief Human Resources Officer | Female | 1976 | 2.29M |
Merck & Co., Inc. Insider Trades
| Date | 30 May |
| Name | Warden Kathy J |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 2863.0921 |
| Date | 30 May |
| Name | THULIN INGE G |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 2863.0921 |
| Date | 30 May |
| Name | Seidman Christine E |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 2863.0921 |
| Date | 30 May |
| Name | RUSSO PATRICIA F |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 2863.0921 |
| Date | 30 May |
| Name | Rothman Paul |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 2863.0921 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 30 May | Warden Kathy J | Director | Acquired | A-Award | 2863.0921 |
| 30 May | THULIN INGE G | Director | Acquired | A-Award | 2863.0921 |
| 30 May | Seidman Christine E | Director | Acquired | A-Award | 2863.0921 |
| 30 May | RUSSO PATRICIA F | Director | Acquired | A-Award | 2863.0921 |
| 30 May | Rothman Paul | Director | Acquired | A-Award | 2863.0921 |